Cochrane Review calls for more R&D on ORS

16 April 2009

Newer polymer-based formulations of oral rehydration solution given to treat diarrhea may offer some benefits over older sugar-salt  formulations, according to a Cochrane Review of recent studies. But the  authors note that more research is required to establish the best  treatment option.

Acute diarrhea is a major cause of childhood death in developing  countries, and is treated with oral rehydration solutions. While ORS  formulations have traditionally contained sugar and salt, new  formulations have been tested that replace the sugar with  sugar-containing poly-mers from rice, wheat, sorghum and maize.

The review focused on 27 trials that included 4,214 participants and  indicated that polymer-based ORS reduced the time that cholera patients  suffered from diarrhea. Polymer-based ORS also decreased the need to  give patients intravenous fluid compared to previous,  higher-concentration sugar-salt solutions, but evidence was limited for  the comparison with less concentrated salt solutions, which are  currently recommended.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight